Blood Cancer and Immunotherapy Laboratory

Advanced CRISPR Tools

Our lab develops advanced in vivo CRISPR technologies to identify and validate the genetic drivers of cancer growth. These discoveries reveal new therapeutic targets and biomarkers that can improve tumour classification, enabling more precise treatment selection. This research helps match cancer patients to the most effective therapies and supports the development of safer and more effective treatments for all patients in the future. 

Pre-clinical Models

A major focus of our lab is modelling human disease in preclinical animal models. We integrate advanced CRISPR genome engineering with mRNA-LNP technology to recreate the genetic alterations that drive human blood cancers. These models allow us to evaluate new targeted cancer treatments and immunotherapies, helping to identify more effective and better tolerated treatment strategies for all cancer patients. 

Advancing Immunotherapy

Our lab is advancing immunotherapy by both improving and simplifying CAR T cell therapy. First, we use CRISPR-based genetic screens to identify factors that enhance immune cell function, helping to improve that effectiveness of CAR T cell therapies. Second, we are developing mRNA nanoparticle technologies that can generate CAR T cells directly within the body. Together, these approaches aim to make immunotherapies safer, more effective and more accessible for cancer patients.